|
|
|
|
|
|
|
|
open access
26 FEB 2016
Introduction
Mortality
rates from cancer have declined over the past 30 years largely because
of early detection strategies, improved surgical approaches, as well as
advances in cancer therapeutics.[1-3] Improvement in survivorship, however, can be associated with other organ injuries, including impact on cardiovascular health.[4] Cardiovascular (CV) disease (CVD) is now the second leading cause of long-term morbidity and mortality among cancer survivors.[1-3, 5, 6]
Conventional chemotherapy and targeted therapies are associated with an
increased risk of cardiac damage, including left ventricular (LV)
dysfunction (LVD) and heart failure (HF),[7, 8]
treatment-induced hypertension, vasospastic and thromboembolic
ischemia, as well as rhythm disturbances, including conduction system
damage and potentially QTc prolongation, that may be rarely
life-threatening. Although some of these cardiac adverse effects are
irreversible and cause progressive CVD, others induce only temporary
dysfunction with no apparent long-term sequelae.[9]
Early and late effects of chest radiation can lead to radiation-induced
heart disease (RIHD), which may involve a spectrum of cardiac
conditions, such as pericardial disease, myocardial fibrosis,
cardiomyopathy, coronary artery disease (CAD), valvular disease, and
arrhythmias in the setting of myocardial fibrosis.[10]
Oncologists face the challenge of treating patients with the best
cancer therapies available without adversely impacting CV health. The
discipline of cardio-oncology has developed in response to the combined
decision making necessary to optimize the care of patients with cancer,
whether they are receiving active treatment or are long-term survivors
after successful treatment. This review will focus on the common CV
issues that may arise during or after cancer therapy, the detection and
monitoring of CV injury, and the best management principles to protect
or minimize the impact of CV issues during the spectrum of cancer
therapies.....
Conclusions
Modern
cancer treatment strategies have led to a significant improvement in
the chances of surviving a diagnosis of cancer for many years. These
gains in overall outcome may be offset by the potential negative impact
of cancer therapy on CV health. Cancer therapies may have short-term and
long-term side effects involving the heart and circulation, as well as
exacerbating and/or unmasking existing heart disease. The development of
CV disease during the course of cancer treatment can adversely impact
the management of the underlying malignancy by interfering with the
optimal doses and timing of lifesaving cancer therapy. In addition, the
development of a potentially important cancer therapy may be halted or
abandoned because of a perceived increased CV risk. The discipline of
cardio-oncology has developed in response to the combined decision
making necessary to optimize the care of patients with cancer, whether
they are receiving active treatment or are long-term survivors after
successful treatment (Fig. 1).
Cardiology and oncology organizations around the world (ie, European
Society for Medical Oncology, American College of Cardiology, ASCO,
European Society of Cardiology, Canadian Cardiovascular Society) are now
recognizing the importance of this collaboration, resulting in the
ongoing development of several clinical practice guidelines and position
statements.[94, 164, 165]
Although these initiatives will provide important guidance for
clinicians on best practices for patients today, many questions remain
unanswered: How can we predict who will develop cardiotoxicity, what is
the best prevention strategy, how should we monitor those at risk of
cardiotoxicity, and what are the best management strategies? There is an
urgent need for collaborative research to address these questions.
Vibrant collaborative partnerships between oncologists, cardiologists,
and other allied health care professionals will play an important role
in the development and promotion of clinical care models, educational
programs (for patients and health care providers), and evidence-based
research to improve the care of patients being treated for cancer.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.